Argent BioPharma Ltd. Updates on SINTEF Collaboration for Chronic Wound Management
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) reports progress in its collaboration with SINTEF on enhancing antimicrobial therapies for chronic wounds and oncologic wound care. The company has advanced its proprietary antimicrobial compounds using nano-encapsulation technology to improve drug efficacy and targeted delivery.
Key achievements include establishing standardized in vitro assays, identifying Synthetic Wound Fluid (SWF) as the optimal testing medium, and selecting promising APIs with pH-dependent antimicrobial activity. The research targets diabetic foot ulcers, pressure sores, post-surgical infections, and non-melanoma skin cancer excisions.
The next phase will focus on refining API combinations for nano-encapsulation and conducting Minimum Inhibitory Concentration studies. The initiative aims to address biofilm formation, antibiotic resistance, and chronic infections in a global advanced wound care market projected to exceed $15 billion by 2030.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) riporta progressi nella sua collaborazione con SINTEF per migliorare le terapie antimicrobiche per le ferite croniche e la cura delle ferite oncologiche. L'azienda ha sviluppato i suoi composti antimicrobici proprietari utilizzando la tecnologia di nano-incapsulamento per migliorare l'efficacia del farmaco e la somministrazione mirata.
I principali risultati includono l'istituzione di saggi in vitro standardizzati, l'identificazione del Fluido Sintetico per Ferite (SWF) come il mezzo di test ottimale e la selezione di principi attivi promettenti con attività antimicrobica dipendente dal pH. La ricerca si concentra sulle ulcere del piede diabetico, le piaghe da decubito, le infezioni post-chirurgiche e le escissioni di tumori cutanei non melanoma.
La fase successiva si concentrerà sul perfezionamento delle combinazioni di principi attivi per il nano-incapsulamento e sulla conduzione di studi sulla Concentrazione Inibitoria Minima. L'iniziativa mira ad affrontare la formazione di biofilm, la resistenza agli antibiotici e le infezioni croniche in un mercato globale avanzato per la cura delle ferite che si prevede supererà $15 miliardi entro il 2030.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) informa sobre los avances en su colaboración con SINTEF para mejorar las terapias antimicrobianas para heridas crónicas y cuidado de heridas oncológicas. La empresa ha avanzado en sus compuestos antimicrobianos patentados utilizando tecnología de nanoencapsulación para mejorar la eficacia del fármaco y la entrega dirigida.
Los logros clave incluyen el establecimiento de ensayos in vitro estandarizados, la identificación del Fluido Sintético para Heridas (SWF) como el medio de prueba óptimo y la selección de ingredientes activos prometedores con actividad antimicrobiana dependiente del pH. La investigación se dirige a úlceras del pie diabético, llagas por presión, infecciones postquirúrgicas y excisiones de cáncer de piel no melanoma.
La próxima fase se centrará en refinar las combinaciones de ingredientes activos para la nanoencapsulación y realizar estudios de Concentración Inhibitoria Mínima. La iniciativa tiene como objetivo abordar la formación de biofilm, la resistencia a los antibióticos y las infecciones crónicas en un mercado global de cuidado avanzado de heridas que se proyecta superará $15 mil millones para 2030.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF)는 만성 상처 및 종양 상처 치료를 위한 항균 요법을 향상시키기 위해 SINTEF와의 협력에서 진전을 보고합니다. 이 회사는 약물의 효능과 표적 전달을 개선하기 위해 나노 캡슐화 기술을 사용하여 독점 항균 화합물을 발전시켰습니다.
주요 성과로는 표준화된 인 비트로 분석법을 설정하고, 최적의 테스트 매체로 합성 상처 액체(SWF)를 식별하며, pH 의존적 항균 활성을 가진 유망한 활성 제제를 선택하는 것이 포함됩니다. 연구는 당뇨병성 발 궤양, 욕창, 수술 후 감염 및 비흑색종 피부암 절제를 목표로 하고 있습니다.
다음 단계는 나노 캡슐화를 위한 활성 제제 조합을 정제하고 최소 억제 농도 연구를 수행하는 데 중점을 둘 것입니다. 이 이니셔티브는 생물막 형성, 항생제 내성 및 만성 감염 문제를 해결하는 것을 목표로 하며, 2030년까지 150억 달러 이상에 이를 것으로 예상되는 글로벌 고급 상처 치료 시장을 겨냥하고 있습니다.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) fait état de progrès dans sa collaboration avec SINTEF pour améliorer les thérapies antimicrobiennes pour les plaies chroniques et les soins des plaies oncologiques. L'entreprise a fait avancer ses composés antimicrobiens propriétaires en utilisant la technologie de nano-encapsulation pour améliorer l'efficacité des médicaments et la délivrance ciblée.
Les réalisations clés comprennent l'établissement de tests in vitro standardisés, l'identification du Fluide Synthétique pour Plaies (SWF) comme milieu de test optimal et la sélection d'ingrédients actifs prometteurs avec une activité antimicrobienne dépendante du pH. La recherche vise les ulcères du pied diabétique, les escarres, les infections post-chirurgicales et les excisions de cancers de la peau non mélanome.
La prochaine phase se concentrera sur le perfectionnement des combinaisons d'ingrédients actifs pour la nano-encapsulation et la réalisation d'études sur la Concentration Inhibitrice Minimale. L'initiative vise à aborder la formation de biofilm, la résistance aux antibiotiques et les infections chroniques dans un marché mondial des soins avancés des plaies qui devrait dépasser 15 milliards de dollars d'ici 2030.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) berichtet über Fortschritte in der Zusammenarbeit mit SINTEF zur Verbesserung von antimikrobiellen Therapien für chronische Wunden und onkologische Wundpflege. Das Unternehmen hat seine proprietären antimikrobiellen Verbindungen mithilfe von Nano-Encapsulation-Technologie weiterentwickelt, um die Wirksamkeit von Arzneimitteln und die zielgerichtete Abgabe zu verbessern.
Zu den wichtigsten Erfolgen gehören die Etablierung standardisierter In-vitro-Tests, die Identifizierung von Synthetic Wound Fluid (SWF) als dem optimalen Testmedium und die Auswahl vielversprechender Wirkstoffe mit pH-abhängiger antimikrobieller Aktivität. Die Forschung konzentriert sich auf diabetische Fußgeschwüre, Druckgeschwüre, postchirurgische Infektionen und Exzisionen von nicht-melanomatischen Hautkrebs.
Die nächste Phase wird sich auf die Verfeinerung von Wirkstoffkombinationen für die Nano-Encapsulation und die Durchführung von Studien zur minimalen Hemmkonzentration konzentrieren. Die Initiative zielt darauf ab, Biofilmbildung, Antibiotikaresistenz und chronische Infektionen in einem globalen Markt für fortschrittliche Wundversorgung anzugehen, der voraussichtlich 15 Milliarden US-Dollar bis 2030 übersteigen wird.
- Advanced wound care market projected to reach $15 billion by 2030, indicating significant market opportunity
- Successfully identified promising APIs with pH-dependent antimicrobial activity
- Established standardized testing protocols and optimal testing medium (SWF)
- Product still in early research phase with no immediate revenue potential
- No clinical trial data or regulatory approvals yet
Advanced wound care market projected to exceed
SINTEF, headquartered in Trondheim,
Key Developments:
- Optimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, improving their targeted drug delivery.
- Key Research Milestones Achieved: Standardized in vitro assays have been established, Synthetic Wound Fluid (SWF) identified as the optimal testing medium, and promising active pharmaceutical ingredients (APIs) with pH-dependent antimicrobial activity selected.
- Addressing Critical Wound Care Needs: The initiative focuses on diabetic foot ulcers, pressure sores, post-surgical infections, and potentially non-melanoma skin cancer (NMSC) excisions, aiming to combat biofilm formation, antibiotic resistance, and chronic infections.
Research Progress:
In the project's first phase, Argent BioPharma identified SWF as the most suitable medium for testing antimicrobial efficacy in chronic wound infections. Multiple APIs were screened, revealing promising candidates whose antimicrobial activity is pH-dependent, informing future formulation strategies.
The next phase will refine API combinations for nano-encapsulation and conduct Minimum Inhibitory Concentration (MIC) studies to evaluate synergistic antimicrobial effects. This research aims to develop solutions for persistent infections, biofilm-related complications, and antibiotic resistance.
Market Potential and Strategic Goals:
With the advanced wound care market projected to exceed
Commitment to Innovation
Argent BioPharma remains committed to developing innovative therapeutic solutions for unmet medical needs.
for further information please contact:
Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 | Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950
|
View original content:https://www.prnewswire.com/news-releases/argent-biopharma-ltd-updates-on-sintef-collaboration-for-chronic-wound-management-302375044.html
SOURCE Argent BioPharma Ltd.
FAQ
What is the market potential for RGTLF's wound care technology?
What are the key developments in RGTLF's collaboration with SINTEF?
What medical conditions does RGTLF's wound care technology target?
What is the next phase of RGTLF's wound care research?
How does RGTLF's nano-encapsulation technology work in wound care?
